8-K filed May 17, 2024, 7:59 PM ET ticker TDC CIK 0000816761

other material confidence high sentiment neutral materiality 0.55

Teradata shareholders approve stock plan amendment adding 3.48M shares; elect three directors

TERADATA CORP /DE/

Amended 2023 Stock Incentive Plan approved with 71.9M for (70%), adding 3.48M shares for future grants.
Class II directors Lisa R. Bacus, Timothy C.K. Chou, John G. Schwarz elected with 77M+ votes each.
Advisory say-on-pay passed with 77.3M for vs 3.0M against; broker non-votes 9.1M.
Ratification of PwC as independent auditor approved with 84.1M for, 5.3M against.
Annual Meeting quorum of 90.1M shares (92% of outstanding) present or represented by proxy.

item 5.02 item 5.07 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000816761-24-000129
form_type: 8-K
ticker: TDC
cik: 0000816761
company_name: TERADATA CORP /DE/
filed_at: 2024-05-17T23:59:59+00:00
discovered_at: 2026-05-14T18:03:22.061929+00:00
generated_at: 2026-06-01T17:55:59.461116+00:00
sec_items: ["5.02", "5.07", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000816761-24-000129
json_url: https://secwatch.observer/filing/0000816761-24-000129.json
markdown_url: https://secwatch.observer/filing/0000816761-24-000129.md
text_url: https://secwatch.observer/filing/0000816761-24-000129.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/816761/000081676124000129/0000816761-24-000129-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/816761/000081676124000129/tdc-20240514.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

5bf386359cea10e8e301ed7a719b252bb02a71d2

TERADATA CORP /DE/ shareholders approved Advisory (non-binding) vote on executive compensation at the 2024-05-14 meeting.

2. An advisory (non-binding) vote on executive compensation ("say-on-pay"). For: 77,262,561 Against: 2,968,099 Abstain: 746,186 Broker Non-Votes: 9,116,473

SEC 8-K Item 5.07 confidence 0.98 SEC evidence

77b6f1abfc23a6000fb56d0a74ba707901a34131

TERADATA CORP /DE/ shareholders approved Election of three Class II directors (Lisa R. Bacus, Timothy C.K. Chou, John G. Schwarz) for three-year terms expiring at the 2027 Annual Meeting at the 2024-05-14 meeting.

1. Election of (i) three Class II directors for three-year terms expiring at the 2027 Annual Meeting to hold office until their respective successors are duly elected and qualified. Class II Directors a. Lisa R. Bacus For: 77,531,179 Against: 2,767,598 Abstain: 678,069 Broker Non-Votes: 9,116,473 b. Timothy C.K. Chou For: 79,248,494 Against: 1,041,365 Abstain: 686,987 Broker Non-Votes: 9,116,473 c. John G. Schwarz For: 77,025,374 Against: 3,269,821 Abstain: 681,651 Broker Non-Votes: 9,116,473

SEC 8-K Item 5.07 confidence 0.95 SEC evidence

98c2dd31ca3c55114d8c004db921f056759a59e0

TERADATA CORP /DE/ shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2023 at the 2024-05-14 meeting.

4. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2023. For: 84,054,300 Against: 5,333,837 Abstain: 705,182

SEC 8-K Item 5.07 confidence 0.98 SEC evidence

f5c9ac05b7063b6448c56667bedc835bd70e1326

TERADATA CORP /DE/ shareholders approved Approval of the Amended 2023 Plan at the 2024-05-14 meeting.

3. The approval of the Amended 2023 Plan. For: 71,903,909 Against: 8,365,446 Abstain: 707,491 Broker Non-Votes: 9,116,473

SEC 8-K Item 5.07 confidence 0.98 SEC evidence

Comparable filings

CRM

Salesforce shareholders approve 34M share equity plan increase, extend term to 2036, all directors re-elected

Salesforce, Inc. June 1, 2026, 4:43 PM ET other_material Items 5.07, 5.02, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

2. An advisory (non-binding) vote on executive compensation ("say-on-pay"). For: 77,262,561 Against: 2,968,099 Abstain: 746,186 Broker Non-Votes: 9,116,473

Comparable filing

Advisory vote to approve the fiscal 2026 compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 493,864,228 117,716,717 668,510 102,463,325

Filing page SEC filing

SIRI

Sirius XM shareholders approve 7.2M share increase in 2024 equity plan, elect directors

SIRIUS XM HOLDINGS INC. June 1, 2026, 4:28 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

2. An advisory (non-binding) vote on executive compensation ("say-on-pay"). For: 77,262,561 Against: 2,968,099 Abstain: 746,186 Broker Non-Votes: 9,116,473

Comparable filing

Election of Directors The holders of our common stock elected the persons listed below as Class I directors. Votes Cast For Votes Withheld Broker Non-Votes Eddy W. Hartenstein 229,472,971 4,921,855 51,448,019 Kristina M. Salen 231,643,217 2,751,609 51,448,019 Jennifer C. Witz 230,660,585 3,734,241 51,448,019 The holders of our common stock elected the persons listed below as Class II directors. Votes Cast For Votes Withheld Broker Non-Votes Evan D. Malone 230,881,893 3,512,933 51,448,019 Jonelle Procope 210,894,725 23,500,101 51,448,019 Anjali Sud 213,150,753 21,244,073 51,448,019

Filing page SEC filing

ESPR

Esperion shareholders approve 7M-share increase to 2022 equity incentive plan

Esperion Therapeutics, Inc. June 1, 2026, 4:22 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

2. An advisory (non-binding) vote on executive compensation ("say-on-pay"). For: 77,262,561 Against: 2,968,099 Abstain: 746,186 Broker Non-Votes: 9,116,473

Comparable filing

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

Filing page SEC filing

LUV

Southwest shareholders approve amended equity plan with 4.75M share increase; all directors elected

SOUTHWEST AIRLINES CO May 20, 2024, 7:59 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

2. An advisory (non-binding) vote on executive compensation ("say-on-pay"). For: 77,262,561 Against: 2,968,099 Abstain: 746,186 Broker Non-Votes: 9,116,473

Comparable filing

3. Proposal 3 – Approval of the Southwest Airlines Co. Amended and Restated 2007 Equity Incentive Plan: VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 408,346,613 28,870,401 1,635,532 90,613,942

Filing page SEC filing

Regulus Therapeutics Inc.

Regulus shareholders approve 2019 Equity Plan amendment adding 9.5M shares

Regulus Therapeutics Inc. May 17, 2024, 7:59 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

2. An advisory (non-binding) vote on executive compensation ("say-on-pay"). For: 77,262,561 Against: 2,968,099 Abstain: 746,186 Broker Non-Votes: 9,116,473

Comparable filing

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

Filing page SEC filing

OSUR

OraSure shareholders approve 3M share increase in stock plan, charter amendment limiting officer liability

ORASURE TECHNOLOGIES INC May 17, 2024, 7:59 PM ET other_material Items 5.02, 5.03, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

2. An advisory (non-binding) vote on executive compensation ("say-on-pay"). For: 77,262,561 Against: 2,968,099 Abstain: 746,186 Broker Non-Votes: 9,116,473

Comparable filing

ITEM 1 . Election of two Class III Directors for Terms Ending in 2027. NAME Votes For Votes Against Abstentions Broker Non-Votes Nancy J. Gagliano, M.D. 57,243,711 4,832,639 46,575 5,007,157 Lelio Marmora 57,332,773 4,732,865 57,287 5,007,157

Filing page SEC filing

HNI

HNI to close Hickory plant, consolidates production; charges $10.3M, saves ~$11M annually

HNI CORP May 20, 2024, 7:59 PM ET other_material Items 2.05, 2.06, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

2. An advisory (non-binding) vote on executive compensation ("say-on-pay"). For: 77,262,561 Against: 2,968,099 Abstain: 746,186 Broker Non-Votes: 9,116,473

Comparable filing

Proposal No. 2 – Ratification of KPMG LLP as the Corporation’s Independent Registered Public Accounting Firm for Fiscal 2024. The Corporation’s shareholders ratified the selection of KPMG LLP as the Corporation’s independent registered public accounting firm for the fiscal year ending December 28, 2024, with votes as follows: %For 1 For Against Abstain 99.33% 41,551,173.283 281,975.938 62,933.098 1 Percentage of votes cast, which excludes abstentions (in accordance with Iowa law).

Filing page SEC filing

Nemaura Medical Inc.

Shareholders approve reverse stock split authorization at ratio of 1:10 to 1:150

Nemaura Medical Inc. May 17, 2024, 7:59 PM ET other_material Items 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

2. An advisory (non-binding) vote on executive compensation ("say-on-pay"). For: 77,262,561 Against: 2,968,099 Abstain: 746,186 Broker Non-Votes: 9,116,473

Comparable filing

On May 9, 2024, the Shareholders of Nemaura Medical Inc. (the “Company”) approved by written consent to authorize amendments to the Articles of Incorporation of the Company (the “Articles”) to effect a reverse stock split of the common stock, par value $0.001 per share, of the Company (the “Common Stock”) ranging in ratio between 1-for-10 and 1-for-150, with one share of Common Stock being issued for a range of between each 10 and 150 shares of Common Stock issued and outstanding, with such final ratio to be determined by the Board following approval thereof by the shareholders of the Company, with any fractional shares of Common Stock resulting therefrom being rounded up to the nearest whole share of Common Stock (the “Reverse Split”), and to amend the Articles to effect the Reverse Split.

Filing page SEC filing

Source: SEC EDGAR

accession 0000816761-24-000129

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.